One hundred forty-two @entity1 underwent surgery and related treatment for advanced stage (III, IV) @entity1149 . One hundred seventeen @entity1 underwent up-front surgery, with a hospital mortality rate of 1.7% (2/117). Kaplan-Meier 5-year survival in this group was 31% (+/- 5). Twenty-five @entity1 underwent neoadjuvant therapy followed by surgical resection, with respective rates of hospital mortality, complete pathologic response, and major pathologic response of 0%, 16%, and 64%. Kaplan-Meier 5-year survival in this latter group was 34% (+/- 11). Of the 16 @entity1 undergoing neoadjuvant therapy who had complete pathologic response or significant downstaging from stage III disease, Kaplan-Meier 5-year survival was 61% (+/- 15). Three clinical observations of interest emerged regarding survival. First, in those @entity1 with postresection FEV1 < 1.0 L, hospital mortality rate was 20%, and there were no 5-year survivors (P < 0.0001). Second, where neoadjuvant therapy was associated with complete pathologic response or significant downstaging of disease, there was a trend for improved survival in the downstaged group, but it did not reach statistical significance (P = 0.14). Third, adjuvant therapy was associated with improved 5-year survival (P = 0.03), particularly for combination chemotherapy and radiotherapy (P = 0.02).

Late stage (III and IV) XXXX : results of surgical resection at Inova Fairfax Hospital.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell cancer of the lung']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell cancer of the lung']
